AU2011217809A1 - Triazolones as fatty acid synthase inhibitors - Google Patents
Triazolones as fatty acid synthase inhibitors Download PDFInfo
- Publication number
- AU2011217809A1 AU2011217809A1 AU2011217809A AU2011217809A AU2011217809A1 AU 2011217809 A1 AU2011217809 A1 AU 2011217809A1 AU 2011217809 A AU2011217809 A AU 2011217809A AU 2011217809 A AU2011217809 A AU 2011217809A AU 2011217809 A1 AU2011217809 A1 AU 2011217809A1
- Authority
- AU
- Australia
- Prior art keywords
- methyl
- dihydro
- cyclopropylcarbonyl
- triazol
- pyrrolidinyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
- C07D407/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4196—1,2,4-Triazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US30670910P | 2010-02-22 | 2010-02-22 | |
US61/306,709 | 2010-02-22 | ||
US35758710P | 2010-06-23 | 2010-06-23 | |
US61/357,587 | 2010-06-23 | ||
PCT/US2011/025661 WO2011103546A1 (en) | 2010-02-22 | 2011-02-22 | Triazolones as fatty acid synthase inhibitors |
Publications (1)
Publication Number | Publication Date |
---|---|
AU2011217809A1 true AU2011217809A1 (en) | 2012-09-06 |
Family
ID=44483349
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AU2011217809A Abandoned AU2011217809A1 (en) | 2010-02-22 | 2011-02-22 | Triazolones as fatty acid synthase inhibitors |
Country Status (13)
Families Citing this family (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MX2012009720A (es) * | 2010-02-22 | 2012-10-09 | Glaxosmithkline Llc | Triazolonas como inhibidores de acido graso sintasa. |
US9505728B2 (en) | 2012-03-09 | 2016-11-29 | Inception 2, Inc. | Triazolone compounds and uses thereof |
MX2015007433A (es) | 2012-12-20 | 2015-12-07 | Inception 2 Inc | Compuestos de triazolona y usos de los mismos. |
EP2943484B1 (en) * | 2013-01-10 | 2017-10-25 | Glaxosmithkline Intellectual Property (No. 2) Limited | Fatty acid synthase inhibitors |
PE20160122A1 (es) | 2013-03-13 | 2016-02-12 | Forma Therapeutics Inc | Compuestos nobles y composiciones para la inhibicion de fasn |
EP3041849A4 (en) | 2013-09-05 | 2017-04-19 | Dow AgroSciences LLC | Methods for producing borylated arenes |
WO2015035059A1 (en) | 2013-09-06 | 2015-03-12 | Inception 2, Inc. | Triazolone compounds and uses thereof |
CA2934257C (en) * | 2013-12-17 | 2022-06-07 | Janssen Pharmaceutica Nv | Imidazolin-5-one derivative useful as fasn inhibitors for the treatment of cancer |
TW201625354A (zh) | 2014-06-16 | 2016-07-16 | 陶氏農業科學公司 | 用於製備氧硼基化芳烴之方法 |
CN104876917B (zh) * | 2015-06-16 | 2017-09-19 | 上海皓元医药股份有限公司 | 用作脂肪酸合成酶抑制剂的三唑酮的合成方法 |
MX2017016669A (es) | 2015-06-18 | 2018-04-13 | Cephalon Inc | Derivados de piperidina 1,4-sustituidos. |
EP3310773B1 (en) | 2015-06-18 | 2020-12-02 | 89Bio Ltd. | Substituted 4-benzyl and 4-benzoyl piperidine derivatives |
TW201722957A (zh) * | 2015-09-15 | 2017-07-01 | 葛蘭素史克智慧財產(第二)有限公司 | 化學化合物 |
TWI767148B (zh) | 2018-10-10 | 2022-06-11 | 美商弗瑪治療公司 | 抑制脂肪酸合成酶(fasn) |
CN113382633A (zh) | 2018-10-29 | 2021-09-10 | 福马治疗股份有限公司 | (4-(2-氟-4-(1-甲基-1H-苯并[d]咪唑-5-基)苯甲酰基)哌嗪-1-基)(1-羟基环丙基)甲酮的固体形式 |
CN114539193A (zh) * | 2022-01-20 | 2022-05-27 | 海南普利制药股份有限公司 | 一种盐酸胺碘酮中间体的制备方法 |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5728834A (en) * | 1996-11-14 | 1998-03-17 | Wyckoff Chemical Company, Inc. | Process for preparation of 4-aryl-1,2,4-triazol-3-ones |
WO2004064730A2 (en) * | 2003-01-14 | 2004-08-05 | Cytokinetics, Inc. | Compounds, compositions and methods |
SE0400850D0 (sv) * | 2004-03-30 | 2004-03-31 | Astrazeneca Ab | Novel Compounds |
EP1784396B8 (en) * | 2004-08-26 | 2011-04-20 | Pfizer Inc. | Pyrazole-substituted aminoheteroaryl compounds as protein kinase inhibitors |
WO2007056170A2 (en) * | 2005-11-02 | 2007-05-18 | Bayer Healthcare Ag | Pyrrolo[2,1-f] [1,2,4] triazin-4-ylamines igf-1r kinase inhibitors for the treatment of cancer and other hyperproliferative diseases |
US8236792B2 (en) * | 2008-05-23 | 2012-08-07 | Janssen Pharmaceutica Nv | Substituted pyrrolidine amides as modulators of the histamine H3 receptor |
MX2012009720A (es) * | 2010-02-22 | 2012-10-09 | Glaxosmithkline Llc | Triazolonas como inhibidores de acido graso sintasa. |
-
2011
- 2011-02-22 MX MX2012009720A patent/MX2012009720A/es unknown
- 2011-02-22 JP JP2012554085A patent/JP5805672B2/ja not_active Expired - Fee Related
- 2011-02-22 KR KR1020127024682A patent/KR20120133386A/ko not_active Application Discontinuation
- 2011-02-22 BR BR112012020976A patent/BR112012020976A2/pt not_active Application Discontinuation
- 2011-02-22 CA CA2790692A patent/CA2790692A1/en not_active Abandoned
- 2011-02-22 EP EP11745417.3A patent/EP2538787B1/en active Active
- 2011-02-22 EA EA201290822A patent/EA201290822A1/ru unknown
- 2011-02-22 ES ES11745417.3T patent/ES2509951T3/es active Active
- 2011-02-22 WO PCT/US2011/025661 patent/WO2011103546A1/en active Application Filing
- 2011-02-22 SG SG2012059291A patent/SG183260A1/en unknown
- 2011-02-22 CN CN2011800201452A patent/CN102858175A/zh active Pending
- 2011-02-22 US US13/579,040 patent/US8802864B2/en not_active Expired - Fee Related
- 2011-02-22 AU AU2011217809A patent/AU2011217809A1/en not_active Abandoned
-
2013
- 2013-11-04 US US14/071,093 patent/US9340529B2/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
JP2013520443A (ja) | 2013-06-06 |
EP2538787A1 (en) | 2013-01-02 |
US20140100213A1 (en) | 2014-04-10 |
US9340529B2 (en) | 2016-05-17 |
SG183260A1 (en) | 2012-09-27 |
US8802864B2 (en) | 2014-08-12 |
MX2012009720A (es) | 2012-10-09 |
CN102858175A (zh) | 2013-01-02 |
EP2538787B1 (en) | 2014-07-16 |
JP5805672B2 (ja) | 2015-11-04 |
US20120316151A1 (en) | 2012-12-13 |
KR20120133386A (ko) | 2012-12-10 |
BR112012020976A2 (pt) | 2017-05-09 |
EP2538787A4 (en) | 2013-07-17 |
CA2790692A1 (en) | 2011-08-25 |
ES2509951T3 (es) | 2014-10-20 |
WO2011103546A1 (en) | 2011-08-25 |
EA201290822A1 (ru) | 2013-03-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP2538787B1 (en) | Triazolones as fatty acid synthase inhibitors | |
US10314845B2 (en) | Benzimidazole derivatives as PI3 kinase inhibitors | |
US20130196971A1 (en) | Fatty acid synthase inhibitors | |
EP2663311A2 (en) | Pyrimidinone derivatives as fatty acid synthase inhibitors | |
US20130172384A1 (en) | Fatty acid synthase inhibitors | |
WO2011056635A1 (en) | Benzimidazoles as fatty acid synthase inhibitors | |
US9725437B2 (en) | Fatty acid synthase inhibitors | |
US8410095B2 (en) | Thiazolopyrimidinone derivatives as PI3 kinase inhibitors |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
MK4 | Application lapsed section 142(2)(d) - no continuation fee paid for the application |